prostatecancernewstoday.com...
This study highlights the "significant improvement" by using erleada and zytiga together vs. just zytiga but then they slip in this statement lower on down in the article: "Other secondary endpoints, including overall survival, time to initiation of chemotherapy, use of chronic opioids, and pain progression, did not differ significantly between the two treatment groups."
Is it really worth it adding the increased side effects if the overall survival is the same?